Polpharma Biologics
Biosimilar developer, Poland. 1 development product across 1 molecule: natalizumab.
First approval in the Atlas: Aug 2023, Tyruko, natalizumab (FDA)
FDAproducts approved1
EMAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Natalizumab | Tyruko PB006 | Aug 2023 | Sep 2023 | · | · | · | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Polpharma Biologics is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Aflibercept | Eiyzey | EMA | Zaklady Farmaceutyczne Polpharma S.A. | Aug 2025 | Sam Chun Dang Pharm |
| Aflibercept | Vgenfli | EMA | Zaklady Farmaceutyczne Polpharma S.A. | Aug 2025 | Sam Chun Dang Pharm |
Chronology
- FDAAug 2023Tyruko, natalizumab
- EMASep 2023Tyruko, natalizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.